Porfimer Sodium EBUS-TBN I-PDT in Advanced Lung Cancer

Phase 2, open-label, single-arm trial of porfimer sodium in lung cancer and solid tumor, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Number of Participants With Adverse Events That Are >= Grade 4 According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.0 at 4 weeks and Number of Participants With Tumor Response at 24 weeks. Started Feb 2020; status: completed.